Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 1236801, 9 pages
https://doi.org/10.1155/2017/1236801
Research Article

A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System

1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Correspondence should be addressed to Zong-Gen Peng

Received 24 January 2017; Revised 23 June 2017; Accepted 19 July 2017; Published 22 August 2017

Academic Editor: Giulia Morsica

Copyright © 2017 Jian-Rui Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. M. Hanafiah, J. Groeger, A. D. Flaxman, and S. T. Wiersma, “Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence,” Hepatology, vol. 57, no. 4, pp. 1333–1342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. G. S. Cooke, M. Lemoine, M. Thursz et al., “Viral hepatitis and the Global Burden of Disease: a need to regroup,” Journal of Viral Hepatitis, vol. 20, no. 9, pp. 600-601, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Tamori, M. Enomoto, and N. Kawada, “Recent advances in antiviral therapy for chronic Hepatitis C,” Mediators of Inflammation, vol. 2016, Article ID 6841628, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. E. R. Feeney and R. T. Chung, “Antiviral treatment of hepatitis C,” The British Medical Journal, vol. 348, g3308, 2014. View at Publisher · View at Google Scholar
  5. A. De Luca, C. Bianco, and B. Rossetti, “Treatment of HCV infection with the novel NS3/4A protease inhibitors,” Current Opinion in Pharmacology, vol. 18, pp. 9–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. E. De Clercq, “Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace,” Reviews in Medical Virology, vol. 25, no. 4, pp. 254–267, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Sarrazin and S. Zeuzem, “Resistance to direct antiviral agents in patients with hepatitis C virus infection,” Gastroenterology, vol. 138, no. 2, pp. 447–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Moreno, T. Berg, T. Tanwandee et al., “Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study,” Journal of Hepatology, vol. 56, no. 6, pp. 1247–1253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Krishnan, J. Beyer, N. Mistry et al., “In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 2, pp. 979–987, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Hedskog, H. Dvory-Sobol, V. Gontcharova et al., “Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy,” Journal of Viral Hepatitis, vol. 22, no. 11, pp. 871–881, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Ferenci and K. R. Reddy, “Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection,” Antiviral Therapy, vol. 16, no. 8, pp. 1187–1201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Lawitz, M. Makara, U. S. Akarca et al., “Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis,” Gastroenterology, vol. 149, no. 4, pp. 971–980.e1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Mullins, W. Gibson, and O. M. Klibanov, “Harvoni (ledipasvir and sofosbuvir) for hepatitis C,” Nurse Practitioner, vol. 40, no. 11, pp. 22–26, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. J.-M. Pawlotsky, “Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus,” Hepatology, vol. 53, no. 5, pp. 1742–1751, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-M. Pawlotsky, “New hepatitis C therapies: the toolbox, strategies, and challenges,” Gastroenterology, vol. 146, no. 5, pp. 1176–1192, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Pawlotsky, “Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens,” Gastroenterology, vol. 151, no. 1, pp. 70–86, 2016. View at Publisher · View at Google Scholar
  17. S. Fourati and J.-M. Pawlotsky, “Virologic tools for HCV drug resistance testing,” Viruses, vol. 7, no. 12, pp. 6346–6359, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Delang, I. Vliegen, P. Leyssen, and J. Neyts, “In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors,” Journal of Hepatology, vol. 56, no. 1, pp. 41–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Jiang, E. Z. Zhang, A. Ardzinski et al., “Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 9, pp. 5456–5465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. D. A. Feigelstock, K. B. Mihalik, and S. M. Feinstone, “Selection of hepatitis C virus resistant to ribavirin,” Virology Journal, vol. 8, article 402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Cheng, K. Chan, H. Yang et al., “Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 5, pp. 2197–2205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Akuta, F. Suzuki, Y. Seko et al., “Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1,” Journal of Medical Virology, vol. 85, no. 6, pp. 1028–1036, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Dietz, S.-E. Schelhorn, D. Fitting et al., “Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis c virus genotype 1-infected patients,” Journal of Virology, vol. 87, no. 11, pp. 6172–6181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-J. Cheng, J.-R. Li, M.-H. Huang et al., “CD36 is a co-receptor for hepatitis C virus E1 protein attachment,” Scientific Reports, vol. 6, Article ID 21808, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-P. Zhu, Z.-G. Peng, Z.-Y. Wu et al., “Host APOBEC3G protein inhibits HCV replication through direct binding at NS3,” PLoS ONE, vol. 10, no. 3, Article ID e0121608, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. R. D'Ambrosio, A. Aghemo, and M. Colombo, “Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C,” Expert Opinion on Drug Safety, vol. 14, no. 3, pp. 473–484, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Akuta, F. Suzuki, T. Fukushima et al., “Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis c virus genotype 1 infection,” Journal of Clinical Microbiology, vol. 52, no. 1, pp. 193–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. E. S. Svarovskaia, H. Dvory Sobol, N. Parkin et al., “Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials,” Clinical Infectious Diseases, vol. 59, no. 12, pp. 1666–1674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Lenz, T. Verbinnen, T.-I. Lin et al., “In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 1878–1887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Lenz, L. Vijgen, J. M. Berke et al., “Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202),” Journal of Hepatology, vol. 58, no. 3, pp. 445–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Buti, M. Riveiro-Barciela, and R. Esteban, “Management of direct-acting antiviral agent failures,” Journal of Hepatology, vol. 63, no. 6, pp. 1511–1522, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Poveda, D. L. Wyles, Á. Mena, J. D. Pedreira, Á. Castro-Iglesias, and E. Cachay, “Update on hepatitis C virus resistance to direct-acting antiviral agents,” Antiviral Research, vol. 108, pp. 181–191, 2014. View at Google Scholar
  33. E. S. Svarovskaia, E. Gane, H. Dvory-Sobol et al., “L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions,” Journal of Infectious Diseases, vol. 213, no. 8, pp. 1240–1247, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. B. B. Summers, J. W. F. Beavers, and O. M. Klibanov, “Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus,” The Journal of pharmacy and pharmacology, vol. 66, no. 12, pp. 1653–1666, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Vallet, F. Viron, C. Henquell et al., “NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1–5,” Antiviral Therapy, vol. 16, no. 7, pp. 1093–1102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Vicenti, A. Rosi, F. Saladini et al., “Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 4, Article ID dkr581, pp. 984–987, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Paolucci, L. Fiorina, A. Piralla et al., “Naturally occurring mutations to HCV protease inhibitors in treatment-nave patients,” Virology Journal, vol. 9, article 245, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Costantino, E. Spada, M. Equestre et al., “Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C,” Virology Journal, vol. 12, no. 1, article 414, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Beloukas, S. King, K. Childs et al., “Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK,” Clinical Microbiology and Infection, vol. 21, no. 11, pp. 1033–1039, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Saeed, U. Andreo, H.-Y. Chung et al., “SEC14L2 enables pan-genotype HCV replication in cell culture,” Nature, vol. 524, no. 7566, pp. 471–475, 2015. View at Publisher · View at Google Scholar · View at Scopus